Overview, Rationale, and Guidance on Testing for Rare Genomic Alterations in Advanced Thyroid Cancer

Download these slides from a live symposium at ASCP 2022 featuring guidance from a pathologist on best practices for biomarker testing in advanced thyroid cancer along with the latest clinical evidence on targeted therapies available for the treatment of RET-altered and BRAF V600E–positive disease.
Juan C. Hernandez-Prera, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 11.69 MB
Released: September 13, 2022

Acknowledgements

Provided by Clinical Care Options, LLC in partnership with the American Society for Clinical Pathology.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines and Genentech, a member of the Roche Group
Lilly

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)

Released: November 14, 2022

Video featuring pathology experts discussing molecular testing in lung and thyroid cancers, from Clinical Care Options (CCO)

Juan C. Hernandez-Prera, MD Jeremy P. Segal, MD, PhD Physicians: maximum of 0.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.5 Medical Knowledge MOC points ABPath MOC: maximum of 0.5 Lifelong Learning points Released: October 24, 2022 Expired: October 23, 2023

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings